Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SF3B3 | Q15393 | 9/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876416 | 0.94 | SF3B3 (0.44) | SF3B3 | |
| SCHEMBL3869393 | 0.93 | SF3B3 (0.40) | SF3B3 | |
| SCHEMBL3876413 | 0.92 | SF3B3 (0.44) | SF3B3 | |
| SCHEMBL3869926 | 0.91 | SF3B3 (0.52) | SF3B3 | |
| SCHEMBL3866183 | 0.90 | SF3B3 (0.44) | SF3B3 | |
| SCHEMBL905723 | 0.87 | SF3B3 (0.49) | SF3B3 | |
| SCHEMBL16075740 | 0.87 | SF3B3 (0.49) | SF3B3 | |
| SCHEMBL1504929 | 0.87 | SF3B3 (0.47) | SF3B3 | |
| SCHEMBL1505220 | 0.86 | SF3B3 (0.44) | SF3B3 | |
| SCHEMBL3865675 | 0.86 | SF3B3 (0.37) | SF3B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576204-B2 | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same | MERCIAN CORPORATION (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20060235002-A1 | Novel physiologically active substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1541570-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE | MERCIAN CORPORATION (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235002-A1 | Novel physiologically active substance | HIF1AN, HIF1A, VEGFA | SF3B3 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.